Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

The effect of simvastatin on the cognitive deficits of children with Neurofibromatosis I (NF1): a randomized, double-blind placebo-controlled study.

- candidate number1864
- NTR NumberNTR542
- Date ISRCTN created14-feb-2006
- date ISRCTN requested13-jan-2006
- Date Registered NTR28-nov-2005
- Secondary IDsN/A 
- Public TitleThe effect of simvastatin on the cognitive deficits of children with Neurofibromatosis I (NF1): a randomized, double-blind placebo-controlled study.
- Scientific TitleThe effect of simvastatin on the cognitive deficits of children with Neurofibromatosis I (NF1): a randomized, double-blind placebo-controlled study.
- ACRONYMNF1 simvastatin trial
- hypothesisStatin-treatment has been shown to normalize the learning- and attention deficits in NF1 +/- mice by decreasing Ras activity. The fact that statins are effective in NF1 mice, combined with their very good safety profile, makes them an ideal candidate drug to treat cognitive impairments associated with NF1 in human patients.
- Healt Condition(s) or Problem(s) studiedNeurofibromatosis type 1 (NF1)
- Inclusion criteriaChildren aged between 8 and 16 years, NF1 diagnosis according to the criteria of the National Institutes of Health, visiting the multidisciplinary NF1-outpatient clinic at the Erasmus MC – Sophia Children’s Hospital; informed consent .
- Exclusion criteriaPathology of the CNS (hydrocephalus, epilepsy, radiotherapy, neurosurgery, etc.), deafness and/or severely impaired vision, use of anti-epilepics and/or neuroleptics.

Additional exclusion-criteria (under METC review):
a. Insufficient cognitive abilities to obtain a reliable score on a verbal IQ test (WISC-RN);
b. Contra-indications for simvastatin-treatment;
c. Planned hospitalization within three months after planned date of inclusion.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 20-jan-2006
- planned closingdate1-mrt-2007
- Target number of participants60
- InterventionsSimvastatin (10 mg/d for month 1, 20 mg/d month 2, 20 mg/d month 3 for children 8-12 years old or 40 mg/d month 3 for children 12-16 years old) or placebo once a day.
- Primary outcome1. Performance on neuropsychological tests on visuospatial memory and attention after 1 and 3 months (Rey Complex Figure test (recall), Bourdon Vos Test);
2. Performance on neurofysiological tests on adaptation of movements after 1 and 3 months (saccade-adaptation test, adaptation of eye-hand coordination);
3. Measurement of the size, number, localization and spectra of UBO’s (unidentified bright objects, hyperintensities on T2 weighed MRI), on T2 MRI and 3D CSI 1H-MRS after 3 months.
- Secondary outcome1. Score on the following neuropsychological tests after 1 and 3 months (after 1 month = under METC review):
1a. Judgement of line orientation test;
1b. Rey Complex Figure Test (copy);
1c. Beery VMI Test;

2. Score on the following neuropsychological tests after 3 months:
2a. IQ-test: WISC-RN;
2b. Verbal Fluency Test;
2c. Trailmaking Test A&B;
2d. Wisconsin Card Sorting Test;
2e. Peabody Picture Vocabulary Test;
2f. Boston Naming Test;
2g. 15 Word-Test;
2h. Stroop Color Word Test;

3. Identification of facial emotions (ANT) Outcome of the following questionnaires after 3 months:
3a. Child Behavior Check List (CBCL parents);
3b. Teacher Report form (TRF);
3c. Child Behavior Check List (CBCL child);
3d. Quality of Life Questionnaire CHQ-CF87 Dutch edition (child) (under METC review);
3e. Quality of Life Questionnaire CHQ-PF50 Dutch edition (parents) (under METC review);
4. Performance on the following neurophysiological tests after 1 and 3 months:
4a. Basic saccade performance;
4b. Smooth pursuit.
- TimepointsN/A
- Trial web siteN/A
- statusstopped: trial finished
- Sponsor/Initiator Erasmus Medical Center, Department of Neurosciences
- Funding
(Source(s) of Monetary or Material Support)
Sophia Children’s Hospital Fund
- Publications
- Brief summaryRecent research has shown that the cognitive phenotype of NF1 +/- mice can be reversed by the administration of statins. Because the majority of children with NF1 suffer from learning disabilities, statins could potentially make a large difference in the morbidity associated with NF1. In a double-blind, randomized placebo-controlled trial, 60 children with NF1 are treated with simvastatin or placebo for three months. The effect of simvastatin treatment will be evaluated using neuropsychologic, neurophysiologic and radiologic parameters.
- Main changes (audit trail)
- RECORD28-nov-2005 - 23-jul-2012

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar